A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- DRUG: Ibrutinib
- DRUG: Bendamustine hydrochloride
- DRUG: Rituximab
- DRUG: Placebo
Sponsor
Janssen Research & Development, LLC
Collaborators